国产99久久精品_欧美日本韩国一区二区_激情小说综合网_欧美一级二级视频_午夜av电影_日本久久精品视频

丹麥Genmab
制藥公司建立在1999年2月成立于哥本哈根

Genmab is dedicated to creating and developing human antibodies to help people suffering from life-threatening and debilitating diseases. Our goal is to serve patients in need of new types of therapy and to build a business that maximizes value for patients and shareholders.

Our Strategy
Genmab's strategy is to maintain a broad pipeline of human antibody products to balance the risk inherent in drug development and maximize our chances for success. To achieve this goal, we have selected disease targets that we believe have a strong scientific and business rationale. We diversify our potential revenue stream by creating products for an array of both validated and novel targets. We also attempt to balance risk through our partnering efforts by licensing some programs at an early stage and others later to create a potentially diversified risk and revenue profile.

Our Team
The Genmab team is comprised of highly skilled and experienced professionals with the dedication, determination and integrity necessary to succeed in the competitive biotechnology field. Our international teams work closely together to streamline and coordinate product discovery, manufacturing, pre-clinical testing, clinical trial design, data management and regulatory submissions.

?

Our Product Pipeline
Genmab's world class discovery and development teams have created and developed an extensive pipeline of products for potential cancer treatment. Our pipeline of fully human antibodies currently consists of 6 products in clinical development as well as numerous pre-clinical programs and other disease targets under exploration. Detailed information on our products can be found on our Products in Development page.

Our Technology
Using the HuMAb-Mouse? transgenic mouse technology licensed from Medarex, Genmab can rapidly create fully human high affinity antibodies which may have less potential to elicit allergic responses or other side effects than previous generations of antibody products which have typically contained mouse or other animal proteins. The HuMAb-Mouse technology, furthermore, eliminates the need for humanization or complicated genetic engineering, which can be time consuming and expensive.

In addition, Genmab has developed UniBody?, a proprietary technology which is used to create a smaller antibody format which may offer several advantages over traditional full size monoclonal antibodies. The UniBody's small size means it has better distribution over targeted areas such as large tumors. The UniBody also binds to only one site and does not produce an immune response, making it possible to treat some forms of cancer, inflammation and asthma that other antibodies cannot treat. Click here for more information on the UniBody technology.

Our Development Capabilities
Genmab's pre-clinical development team works diligently to select the best antibody candidates for development. A panel of antibodies is generated and put through a rigorous series of laboratory functional assays designed to identify the characteristics of the best therapeutic product. Following this in vitro testing, the product candidate is evaluated in vivo using animal disease models prior to initiation human clinical trials. Our in house regulatory, clinical development and data management teams then use their international expertise to move Genmab's products through the clinic.

?